BriaCell Therapeutics Cor...

NASDAQ: BCTX · Real-Time Price · USD
4.00
-0.10 (-2.44%)
At close: May 02, 2025, 3:59 PM
4.00
0.00%
After-hours: May 02, 2025, 05:52 PM EDT

Company Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer.

Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer.

The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.

BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. logo
Country CA
IPO Date Mar 14, 2012
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Dr. William V. Williams FCPA, M.D.

Contact Details

Address:
Bellevue Centre
West Vancouver, BC
CA
Website https://www.briacell.com

Stock Details

Ticker Symbol BCTX
Exchange NASDAQ
Fiscal Year August - July
Reporting Currency USD
CIK Code 0001610820
CUSIP Number 10778Y302
ISIN Number CA1079301091
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. William V. Williams FCPA, M.D. Chief Executive Officer, President & Director
Gadi Levin B.Com., C.A., CPA, M.B.A. Chief Financial Officer & Corporate Secretary
Dr. Charles Louis Wiseman FACP, M.D. Founder, Principal Research Advisor & Member of Scientific Advisory Board
Dr. Giuseppe Del Priore M.D., M.P.H., MPH Chief Medical Officer
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
May 01, 2025 SCHEDULE 13G Filing
Apr 28, 2025 8-K Current Report
Apr 28, 2025 424B4 Filing
Apr 28, 2025 424B4 Filing
Apr 24, 2025 S-1MEF Filing
Apr 24, 2025 CERT Filing
Apr 24, 2025 8-A12B Filing
Apr 23, 2025 S-1/A [Amend] Filing
Apr 22, 2025 FWP Filing
Apr 22, 2025 S-1 Filing